HBM Healthcare Investments refers to its media release dated 30 January 2023. Dr Andreas Wicki has recovered from his health matters and will fully resume his duties as Chief Executive Officer of HBM Healthcare Investments and with the investment adviser HBM Partners as of Monday 3rd April. The Boards of Directors and the employees of HBM Healthcare Investments and HBM Partners would like to thank Chairman Hans Peter Hasler for his increased commitment over the past weeks and are delighted to welcome Andreas Wicki back.
HBM Healthcare Investments also announces the closing of a new investment of USD 12 million in the private US-based company ArriVent Biopharma. The investment is part of ArriVent’s USD 155 million oversubscribed Series B financing. The proceeds of the financing will be used to support pivotal Phase 3 and additional studies with ArriVent’s lead product candidate furmonertinib as well as the continued expansion of its pipeline.
Furmonertinib, a highly brain-penetrating, mutation-specific EGFR kinase inhibitor, is approved in China as a cancer therapy for patients with EGFR-mutated non-small cell lung cancer. Furmonertinib is being developed in China by Allist Pharmaceuticals and in the rest of the world by ArriVent Biopharma.
.